Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials

Authors

• Yu Mi Kang, Harvard Medical School Division of Endocrinology, Diabetes, and Hypertension, Boston, MA
• Erin A. Bohula, Harvard Medical School Division of Cardiovascular Medicine, Boston, MA
• A Michael Lincoff, Case Western Reserve University College of Medicine, Cleveland, OH
• Donna H. Ryan, Pennington Biomedical Research Center, Baton Rouge, LA
• KyungAh Im, Harvard Medical School Division of Cardiovascular Medicine, Boston, MA
• Colleen Thomas, Harvard Medical School Division of Cardiovascular Medicine, Boston, MA
• Marc S. Sabatine, Harvard Medical School Division of Cardiovascular Medicine, Boston, MA
• Benjamin M. Scirica, Harvard Medical School Division of Cardiovascular Medicine, Boston, MA

Document Type

Article

Publication Date

5-8-2025

Publication Title

Diabetes, Obesity, and Metabolism

First Page

4017

Last Page

4021

DOI

10.1111/dom.16424

Rights

© 2025 John Wiley & Sons Ltd.

Recommended Citation

Kang, Yu Mi; Bohula, Erin A.; Lincoff, A Michael; Ryan, Donna H.; Im, KyungAh; Thomas, Colleen; Sabatine, Marc S.; and Scirica, Benjamin M., "Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials" (2025). LSU-LCMC Cancer Center Faculty Publications. 86.
https://digitalscholar.lsuhsc.edu/llcc_facpubs/86
10.1111/dom.16424